Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease.

"Declaration of personal interests : Drs Mark I. Avigan, Lara Dimick‐Santos and Frank A. Anania have no conflict of interest related to this paper. Drs Naga Chalasani and James H. Lewis serve as consultants to several pharmaceutical companies for activities related to DILI, but have not derived any financial or other compensation from activities related to developing this Best Practices document. Dr Benjamin L. Shneider has no conflicts of interest. Drs Melissa Palmer and John F. Marcinak were full‐time employees of Takeda at the time of writing and preparation of this manuscript. Drs. Arie Regev, William Treem and Daniel Seekins are full‐time employees of Eli Lilly, Takeda, and Bristol‐Myers Squibb respectively. Declaration of funding interests : None."

"Declaration of funding interests: None."